477541-32-5

Upstream product

• 619-55-6 para-methylbenzamide 
• 157169-68-1 2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)acetic acid methyl ester 
• 105983-77-5 methyl 4-bromo-3-oxopentanoate 
• 124-63-0 methanesulfonyl chloride 
• 157169-71-6 2-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]ethanol 
• 30414-53-0 methyl propanoyl acetate 
• 1071-73-4 5-Hydroxy-2-pentanone 
• 1383439-54-0 C₂₀H₁₉NO₃ 
• 1352085-98-3 3-bromo-4-carbonylpentyl benzoate 

Downstream Products

• 1352085-91-6 3-{2-ethyl-4-[2-(5-methyl-2-p-tolyloxazol-4-yl)ethoxy]phenyl}propanoic acid 
• 1383439-81-3 C₂₅H₂₉NO₄ 
• 877152-65-3 methyl 2-methyl-c-5-{4-[2-(5-methyl-2-(4-methylphenyl)oxazol-4-yl)ethoxy]phenyl}-1,3-dioxane-r-2-carboxylate 
• 1060279-82-4 methyl 2-methyl-c-5-{4-[2-(5-methyl-2-(4-methylphenyl)oxazol-4-yl)ethoxy]benzyl}-1,3-dioxane-r-2-carboxylate 
• 1065331-89-6 3-(2-(5-methyl-2-p-tolyloxazol-4-yl)ethoxy)benzaldehyde 

Relevant academic research and scientific papers

Design and synthesis of 3-(2-ethyl-4-{2-[2-(4-fluorophenyl)- 5-methyloxazol-4-yl]ethoxy}phenyl)propanoic acid: A novel triple-acting PPARα, -γ, and -δ Agonist

The design and synthesis of triple-acting PPARα, -γ, and -δ agonist 3-(2-ethyl-4-{2-[2-(4-fluorophenyl)-5-methyloxazol-4-yl]- ethoxy}phenyl)propanoic acid (1a) is described. The compound possesses a potent triple-acting PPARα, -γ, and -δ agonist profile with an EC50 of 0.029, 0.013, and 0.029 μM, respectively. The synthetic route, involving the synthesis of oxazole rings as the key step, starts from commercially available 3-oxopentanoic acid methyl ester and 3- hydroxyacetophenone to afford the target compound 1 with an overall yield of 32%.

NOVEL HETEROCYCLIC DERIVATIVES AND MEDICINAL USE THEREOF

The novel heterocyclic derivative of the present invention is a novel heterocyclic derivative having the formula (I') wherein R1 is a hydrogen atom or C1-6 alkyl, R2 is -CO-C(R4)=C(R4)-R5 w